Pan-PIM inhibition has demonstrated therapeutic efficacy in a phase I study of LGH447 in 54 patients with relapsed/refractory multiple myeloma (RRMM).20 The overall response rate was 10.4%, with a minor response or greater in 20.8% and stable disease or greater in 68.8%.20 Therefore, identifying the tumour types that may be more sensitive to PIM inhibition will be important for future PIM inhibitor trials. This evidence concerns the gene PIM1 and AL amyloidosis.